Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

NCT04639245 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Terminated due to slow accrual.

Conditions

Anatomic Stage IV Breast Cancer AJCC v8
Metastatic Lung Non-Small Cell Carcinoma
Metastatic Malignant Solid Neoplasm
Metastatic Triple-Negative Breast Carcinoma
Metastatic Urothelial Carcinoma
Stage IV Lung Cancer AJCC v8

Interventions

DRUG: Atezolizumab
DRUG: Cyclophosphamide
DRUG: Fludarabine
BIOLOGICAL: MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells
BIOLOGICAL: PD1 Inhibitor

Sponsor

Fred Hutchinson Cancer Center

Collaborators

[object Object]